[ CANbridge Life Sciences raises $25M in Series B funding ]
CANbridge Life Sciences has raised $25 million in Series B funding.
Founded in 2012, CANbridge Life Sciences is a clinical-stage bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). It develops partnerships with Western bio-pharmaceutical companies, with clinical-stage pharmaceutical, medical device or diagnostic products, that are either unavailable in China/North Asia or address medical needs that are underserved in the region.
the company will use the new financing for the clinical trial development of its two lead compounds, CAN008 and CAN017, in China.
|Founder / CEO||James Xue|
|Qiming Venture Partners|
|Biossom Investment Management|
|Previous Investors||Qiming Venture Partners|